Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.

El-Mesery M, Trebing J, Schäfer V, Weisenberger D, Siegmund D, Wajant H.

Cell Death Dis. 2013 Nov 14;4:e916. doi: 10.1038/cddis.2013.402.

2.

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Brunekreeft KL, Strohm C, Gooden MJ, Rybczynska AA, Nijman HW, Grigoleit GU, Helfrich W, Bremer E, Siegmund D, Wajant H, de Bruyn M.

Mol Cancer. 2014 Apr 17;13:85. doi: 10.1186/1476-4598-13-85.

4.

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H.

Cell Death Dis. 2014 Jan 30;5:e1035. doi: 10.1038/cddis.2013.555.

5.

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.

Bremer E, de Bruyn M, Samplonius DF, Bijma T, ten Cate B, de Leij LF, Helfrich W.

J Mol Med (Berl). 2008 Aug;86(8):909-24. doi: 10.1007/s00109-008-0348-9. Epub 2008 May 27.

6.

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.

Dicker F, Kater AP, Fukuda T, Kipps TJ.

Blood. 2005 Apr 15;105(8):3193-8. Epub 2004 Aug 31.

PMID:
15339846
7.

Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.

Wajant H, Moosmayer D, Wüest T, Bartke T, Gerlach E, Schönherr U, Peters N, Scheurich P, Pfizenmaier K.

Oncogene. 2001 Jul 5;20(30):4101-6.

8.

A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.

Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H.

J Mol Med (Berl). 2006 Sep;84(9):785-97. Epub 2006 Aug 4.

PMID:
16924474
9.

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W.

Int J Cancer. 2004 Mar 20;109(2):281-90.

10.

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E.

Mol Cancer. 2010 Nov 23;9:301. doi: 10.1186/1476-4598-9-301.

11.

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3.

12.

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.

Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K.

Cell Death Dis. 2012 Apr 12;3:e295. doi: 10.1038/cddis.2012.29.

13.

Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.

Kojima Y, Nakayama M, Nishina T, Nakano H, Koyanagi M, Takeda K, Okumura K, Yagita H.

J Biol Chem. 2011 Dec 16;286(50):43383-93. doi: 10.1074/jbc.M111.309377. Epub 2011 Oct 21.

14.
15.

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.

Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K, Gerspach J.

Cell Death Dis. 2010 Aug 26;1:e68. doi: 10.1038/cddis.2010.45.

16.

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W.

Cancer Immunol Immunother. 2008 Feb;57(2):233-46. Epub 2007 Jul 31.

PMID:
17665197
17.

Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.

Wang LH, Ni CW, Lin YZ, Yin L, Jiang CB, Lv CT, Le Y, Lang Y, Zhao CY, Yang K, Jiao BH, Yin J.

Tumour Biol. 2014 Feb;35(2):1157-68. doi: 10.1007/s13277-013-1155-7. Epub 2013 Nov 26.

PMID:
24272336
18.

Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.

Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H.

Hepatology. 2013 Feb;57(2):625-36. doi: 10.1002/hep.26082. Epub 2013 Jan 8.

PMID:
22991197
19.

Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.

Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.

20.

TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.

Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S.

Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27.

PMID:
12506034

Supplemental Content

Support Center